Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $120.00 Price Target at Morgan Stanley

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective upped by Morgan Stanley from $100.00 to $120.00 in a report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Other analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 1st. Leerink Partners raised their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Royal Bank Of Canada raised their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Weiss Ratings lowered shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, May 20th. Finally, JPMorgan Chase & Co. increased their price target on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $93.83.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $86.78 on Thursday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals has a fifty-two week low of $15.01 and a fifty-two week high of $95.49. The business has a 50 day moving average price of $77.76 and a two-hundred day moving average price of $69.86. The firm has a market cap of $12.22 billion, a PE ratio of -40.36 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.Arrowhead Pharmaceuticals’s quarterly revenue was down 86.4% on a year-over-year basis. During the same period in the prior year, the company posted $2.75 EPS. Sell-side analysts expect that Arrowhead Pharmaceuticals will post -3.09 earnings per share for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the sale, the director owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This represents a 5.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Large investors have recently bought and sold shares of the business. M&T Bank Corp grew its stake in shares of Arrowhead Pharmaceuticals by 2,569.6% in the fourth quarter. M&T Bank Corp now owns 240,634 shares of the biotechnology company’s stock worth $15,976,000 after purchasing an additional 231,620 shares in the last quarter. Kornitzer Capital Management Inc. KS bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $2,375,000. Baader Bank Aktiengesellschaft bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $912,000. State of New Jersey Common Pension Fund D acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $2,820,000. Finally, SBI Okasan Asset Management Co.Ltd. acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $2,541,000. Institutional investors own 62.61% of the company’s stock.

Key Stories Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported topline Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran, with both studies meeting the primary endpoint of triglyceride reduction versus placebo; the drug also showed meaningful reductions in acute pancreatitis risk, which investors view as a major de-risking event. Article Title
• Positive Sentiment: Analysts responded favorably to the data, with Piper Sandler reaffirming an overweight rating and raising its price target to $126, and Morgan Stanley lifting its target to $120, reinforcing expectations for further upside if commercialization progresses. Article Title
• Positive Sentiment: Coverage highlighted Arrowhead’s stock move to a new 52-week high and described the plozasiran win as a validation of the company’s late-stage pipeline, with some commentary suggesting broader FDA approval and expanded commercialization potential. Article Title
• Neutral Sentiment: Additional reports noted that Arrowhead’s ARO-033 first-in-human trial showed early safety progress, which is constructive for the pipeline but less immediately important than the plozasiran catalyst. Article Title
• Negative Sentiment: No major negative company-specific news was provided in the recent items, though one market note flagged that the stock’s valuation has run up sharply, which could make further gains more dependent on execution and regulatory follow-through. Article Title

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.